Rare obesity disease player Rhythm Pharma sets out in search of a $115M IPO windfall
A year after the team at Boston-based Rhythm Pharmaceuticals posted some compelling but limited Phase II data on its lead rare disease drug, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
